X4 Pharmaceuticals Stock Analysis

XFOR Stock Analysis Notes

About 61.0% of the company outstanding shares are owned by institutional investors. The book value of X4 Pharmaceuticals was at this time reported as 0.31. The company recorded a loss per share of 0.57. X4 Pharmaceuticals last dividend was issued on the 14th of March 2019. The entity had 1:6 split on the 14th of March 2019. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. The company was founded in 2010 and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. For more information please call Paula Ragan at 857 529 8300 or visit https://www.x4pharma.com.

X4 Pharmaceuticals Investment Alerts

X4 Pharmaceuticals Upcoming and Recent Events

XFOR Largest EPS Surprises

View All Earnings Estimates

XFOR Stock Institutional Investors

Note, although X4 Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

XFOR Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 181.37 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate X4 Pharmaceuticals's market, we take the total number of its shares issued and multiply it by X4 Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

XFOR Profitablity

Management Efficiency

X4 Pharmaceuticals has return on total asset (ROA) of (0.4438) % which means that it has lost $0.4438 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6167) %, meaning that it created substantial loss on money invested by shareholders. X4 Pharmaceuticals' management efficiency ratios could be used to measure how well X4 Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/04/2024, Return On Tangible Assets is likely to drop to -0.82. In addition to that, Return On Capital Employed is likely to drop to -0.91. At this time, X4 Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 05/04/2024, Net Tangible Assets is likely to grow to about 68.5 M, while Non Current Assets Total are likely to drop slightly above 19.2 M.

Technical Drivers

As of the 4th of May, X4 Pharmaceuticals owns the standard deviation of 6.37, and Market Risk Adjusted Performance of 0.5605. In connection with fundamental indicators, the technical analysis model lets you check timely technical drivers of X4 Pharmaceuticals, as well as the relationship between them. Strictly speaking, you can use this information to find out if the entity will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for X4 Pharmaceuticals, which can be compared to its peers in the sector. Please check out X4 Pharmaceuticals market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if X4 Pharmaceuticals is priced more or less accurately, providing market reflects its prevailing price of 1.15 per share. Given that X4 Pharmaceuticals is a hitting penny stock territory we urge to closely look at its total risk alpha.

X4 Pharmaceuticals Price Movement Analysis

X4 Pharmaceuticals Insider Trading Activities

X4 Pharmaceuticals Predictive Daily Indicators

X4 Pharmaceuticals Forecast Models

X4 Pharmaceuticals' time-series forecasting models are one of many X4 Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary X4 Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how X4 Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling XFOR shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as X4 Pharmaceuticals. By using and applying XFOR Stock analysis, traders can create a robust methodology for identifying XFOR entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. XFOR analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. XFOR analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

X4 Pharmaceuticals stock analysis indicators help investors evaluate how X4 Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading X4 Pharmaceuticals shares will generate the highest return on investment. By understating and applying X4 Pharmaceuticals stock analysis, traders can identify X4 Pharmaceuticals position entry and exit signals to maximize returns.

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Is X4 Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.